Pain Related Quality of Life in Neurofibromatosis Type 1: A Narrative Review.

IF 3.2 2区医学 Q2 CLINICAL NEUROLOGY

Current Pain and Headache Reports Pub Date : 2024-11-01 Epub Date: 2024-06-27 DOI:10.1007/s11916-024-01283-x

Karina Stech, Behnum Habibi

{"title":"Pain Related Quality of Life in Neurofibromatosis Type 1: A Narrative Review.","authors":"Karina Stech, Behnum Habibi","doi":"10.1007/s11916-024-01283-x","DOIUrl":null,"url":null,"abstract":"Purpose of review: The purpose of this narrative review is to summarize pain symptomatology and mechanisms in neurofibromatosis type 1 (NF1), discuss the pain related quality of life impacts of NF1, and discuss the literature exploring interventions to improve quality of life.Recent findings: Chronic pain in NF1 is described as headache and non-headache pain. The literature describes mechanisms contributing to neuronal hyperexcitability in the setting of reduced neurofibromin as key contributors to pain in NF1. Pain in NF1 negatively impacts quality of life with pain interference, depression, anxiety, and cognitive functioning acting as important mediators. Mitogen-activated protein kinase (MEK) inhibitors are pharmacologic agents that interfere with pain mechanisms. Mind-body interventions improve coping skills to improve quality of life. Chronic pain in NF1 is heterogeneous with negative impacts on quality of life. New developments in pharmacological and non-pharmacological interventions offer promising approaches to pain management and quality of life improvement. Additional research is necessary to validate the use of MEK inhibitors and mind-body interventions in the treatment of NF1.","PeriodicalId":50602,"journal":{"name":"Current Pain and Headache Reports","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pain and Headache Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11916-024-01283-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The purpose of this narrative review is to summarize pain symptomatology and mechanisms in neurofibromatosis type 1 (NF1), discuss the pain related quality of life impacts of NF1, and discuss the literature exploring interventions to improve quality of life.

Recent findings: Chronic pain in NF1 is described as headache and non-headache pain. The literature describes mechanisms contributing to neuronal hyperexcitability in the setting of reduced neurofibromin as key contributors to pain in NF1. Pain in NF1 negatively impacts quality of life with pain interference, depression, anxiety, and cognitive functioning acting as important mediators. Mitogen-activated protein kinase (MEK) inhibitors are pharmacologic agents that interfere with pain mechanisms. Mind-body interventions improve coping skills to improve quality of life. Chronic pain in NF1 is heterogeneous with negative impacts on quality of life. New developments in pharmacological and non-pharmacological interventions offer promising approaches to pain management and quality of life improvement. Additional research is necessary to validate the use of MEK inhibitors and mind-body interventions in the treatment of NF1.

查看原文本刊更多论文

神经纤维瘤病 1 型患者与疼痛相关的生活质量：叙述性综述。

综述目的：这篇叙述性综述旨在总结 1 型神经纤维瘤病（NF1）的疼痛症状和机制，讨论 NF1 与疼痛相关的生活质量影响，并讨论探讨改善生活质量的干预措施的文献：NF1的慢性疼痛分为头痛和非头痛两种。文献描述了在神经纤维瘤蛋白减少的情况下导致神经元过度兴奋的机制，这是导致 NF1 患者疼痛的关键因素。NF1 患者的疼痛对生活质量有负面影响，疼痛干扰、抑郁、焦虑和认知功能是重要的介导因素。丝裂原活化蛋白激酶（MEK）抑制剂是干扰疼痛机制的药物。身心干预可提高应对技能，从而改善生活质量。NF1 患者的慢性疼痛具有异质性，对生活质量有负面影响。药理和非药理干预措施的新进展为疼痛管理和生活质量改善提供了有希望的方法。有必要开展更多研究，以验证 MEK 抑制剂和身心干预在治疗 NF1 中的应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Pain and Headache Reports CLINICAL NEUROLOGY-

CiteScore

6.10

自引率

2.70%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings regarding the diagnosis, treatment, and management of pain and headache. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care and prevention of pain and headache. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as anesthetic techniques in pain management, cluster headache, neuropathic pain, and migraine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.